Abstract
The development of non-invasive screening for early diagnosis as well as clinical predictors to guide personalized effective targeted therapy could substantially improve oncological outcomes of patients with colorectal cancer (CRC). In this review it is discussed the potential increase of current early diagnosis rate of 40% with colonoscopy [1] to over 90% sensitivity rates with whole genome sequencing of circulating cell-free DNA robust analysis with artificial intelligence as a screening tool [2]. Moreover, multi-regional intratumor heterogeneity and matched circulating cell-free DNA mutational land scape identification with www.iswwatches.com Next generation sequencing could be used as clinical predictors to select effective targeted drugs for meaningful treatment of individual patients [3-5].

(Citation: Gastric & Breast Cancer 2021; 16(1): 72-78)

Back

PDF Version